Nobori Dual Antiplatelet Therapy as Appropriate Duration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01514227

Recruitment Status : Completed

First Posted : January 23, 2012

Last Update Posted : January 27, 2017

Sponsor:

Information provided by (Responsible Party):

Associations for Establishment of Evidence in Interventions

Study Description

Brief Summary:

NIPPON trial is a prospective, randomized, trial comparing 6 and 18 months Dual Antiplatelet Therapy (DAPT) following Nobori stent deployment.

Condition or disease	Intervention/treatment	Phase
Coronary Artery Disease	Drug: Aspirin or thienopyridine Drug: Aspirin and thienopyridine	Phase 4

Study Design


Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	3773 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	Nobori Dual Antiplatelet Therapy as Appropriate Duration.
Study Start Date :	December 2011
Actual Primary Completion Date :	June 2016
Actual Study Completion Date :	June 2016

Resource links provided by the National Library of Medicine

Drug Information available for: Aspirin

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Short-term DAPT (6 months) group 6 months DAPT (aspirin and thienopyridine) prescription following Nobori stent	Drug: Aspirin or thienopyridine Subjects randomized 6 month DAPT will be prescribed either aspirin or thienopyridine (clopidogrel or ticlopidine) following 6 months DAPT for the duration of study, which is left on the physician's discretion.
Experimental: Long-term DAPT (18 months) group 18 months DAPT (aspirin and thienopyridine) prescription following Nobori stent	Drug: Aspirin and thienopyridine Subjects randomized 18 month DAPT will be prescribed both aspirin and thienopyridine (clopidogrel or ticlopidine) for 18 month after stenting.

Outcome Measures

Primary Outcome Measures :

Net adverse clinical and cerebral event (NACCE) [ Time Frame: 18 months ]
NACCE include all-cause death, non-fatal myocardial infarction, cerebrovascular events, and major bleeding.

Secondary Outcome Measures :

All-cause death [ Time Frame: 18 months ]
Non-fatal myocardial infarction [ Time Frame: 18 months ]
Cerebrovascular events [ Time Frame: 18 months ]
Major bleeding [ Time Frame: 18 months ]
Rate of target lesion revascularization [ Time Frame: 18 months ]
Minor bleeding [ Time Frame: 18 months ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	20 Years to 80 Years (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Subjects > 20 years old
Undergoing percutaneous intervention with Nobori deployment
No contraindication to prolonged DAPT

Exclusion Criteria:

Subjects absolutely necessitating continuous DAPT
Planned surgery necessitating discontinuation of antiplatelet therapy after enrollment.
Active pathological bleeding
Status of cardiogenic shock at enrollment
Pregnant women
Life expectancy of < 1.5 years
Subjects unable to give informed consent
Episode of stroke < 6 months
Subjects with allergies or hypersensitivity to material of coating, Biolimus A9, and antiplatelet drugs.
Subjects treated with other kind of DES or BMS during the index procedure
Previous intervention with DES < 6 months.
Study participation impractical per investigator judgment

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01514227

Locations


Japan
Non-profit organization Associations for Establishment of Evidence in Interventions
Minato-ku, Tokyo, Japan, 105-0013

Sponsors and Collaborators

Associations for Establishment of Evidence in Interventions

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Nakamura M, Iijima R, Ako J, Shinke T, Okada H, Ito Y, Ando K, Anzai H, Tanaka H, Ueda Y, Takiuchi S, Nishida Y, Ohira H, Kawaguchi K, Kadotani M, Niinuma H, Omiya K, Morita T, Zen K, Yasaka Y, Inoue K, Ishiwata S, Ochiai M, Hamasaki T, Yokoi H; NIPPON Investigators. Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation. JACC Cardiovasc Interv. 2017 Jun 26;10(12):1189-1198. doi: 10.1016/j.jcin.2017.04.019.


Responsible Party:	Associations for Establishment of Evidence in Interventions
ClinicalTrials.gov Identifier:	NCT01514227 History of Changes
Other Study ID Numbers:	NIPPON 5.0
First Posted:	January 23, 2012 Key Record Dates
Last Update Posted:	January 27, 2017
Last Verified:	January 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Additional relevant MeSH terms:


Coronary Artery Disease Myocardial Ischemia Coronary Disease Heart Diseases Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Aspirin Anti-Inflammatory Agents, Non-Steroidal Analgesics, Non-Narcotic Analgesics	Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Antirheumatic Agents Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Platelet Aggregation Inhibitors Cyclooxygenase Inhibitors Enzyme Inhibitors Antipyretics

To Top